Increasing the Accuracy of In Vivo Models for Oncolytic Adenovirus Vectors with a Syrian Hamster Model

SLU ID 03-016 | Syrian Hamster Model for Oncolytic Adenovirus Vectors

Intellectual Property Status

Seeking

  • Proprietary non-patented intellectual property

  • Know-how based

  • Tangible material

  • Licensees

  • Development partner

  • Commercial partner

  • Investment

  • University spin out company

Background

Using genetically modified replication-competent (i.e., oncolytic) adenovirus vectors to infect cancer cells and destroy them while having acceptable toxicity in normal tissue is a potential approach to treating cancer. Most studies in this field have investigated the efficiency of these vectors in immunodeficient mice bearing human tumor xenografts. However, this model doesn't fully address the situation in human cancer patients being treated with oncolytic adenovirus because the mouse is immunodeficient as well as non-permissive or semi-permissive for replication of human adenoviruses.

Overview

Researchers at Saint Louis University have developed a Syrian hamster model to enable the evaluation of the safety and efficacy of oncolytic adenovirus vectors for treating cancers and other diseases.

Benefits

The potential advantages of this technology over existing solutions include:

  • Increase the accuracy of in vivo models used to test the safety and efficacy of oncolytic adenovirus vectors

  • Minimize the cost of testing the safety and efficacy of oncolytic adenovirus vectors

Applications

Potential applications of this technology include:

  • Cancer research

  • Drug development

Opportunity

Saint Louis University offers non-exclusive licenses for this technology.